Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3
The Journal of Clinical Endocrinology & Metabolism · 18.08.2023 · 108 (9) · e698-e703
DOI: 10.1210/clinem/dgad181 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 30.03.2023. Verfasst von Na Eun Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: Thyroid Nodule, Adenocarcinoma, Thyroid Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Context
Molecular testing has improved risk stratification and increased nonoperative management for patients with indeterminate thyroid nodules, but data on the long-term outcomes of current molecular tests Afirma Gene Sequencing Classifier (GSC) and Thyroseq v3 are limited.
Objective
To determine the rate of delayed operation and the false negative rate of the Afirma GSC and Thyroseq v3 in Bethesda III and IV thyroid nodules.
Methods
Prospective follow-up of a single center, randomized, clinical trial comparing the performance of Afirma GSC and Thyroseq v3 in the diagnosis of indeterminate thyroid nodules at the University of California, Los Angeles (UCLA). Consecutive participants who underwent thyroid biopsy in the UCLA health system with Bethesda III and IV cytology from August 2017 to November 2019. The main outcome measure was false negative rate of molecular testing.
Results
Of 176 indeterminate nodules with negative or benign molecular test results, 14 (8%) nodules underwent immediate resection, with no malignancies found on surgical pathology. Nonoperative management with active surveillance was pursued for 162 (92%) nodules with benign or negative test results. The median surveillance was 34 months (range 12-60 months), and 44 patients were lost to follow-up. Of 15 nodules resected during surveillance, 1 malignancy was found (overall false negative rate of 0.6%). This was a 2.7 cm minimally invasive Hurthle cell carcinoma that initially tested negative with Thyroseq v3 and underwent delayed resection due to sonographic growth during surveillance.
Conclusions
The majority of Bethesda III/IV thyroid nodules with negative or benign molecular test results are stable over 3 years of follow-up. These findings support the high sensitivity of current molecular tests and their role in ruling out malignancy in indeterminate thyroid nodules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
- Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.
- Department of Biostatistics, University of California, Los Angeles, CA 90095, USA.
- Division of Endocrinology, Diabetes and Metabolism, UCLA David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
ORCID-Profile: Na Eun Kim, Rajam S Raghunathan, Elena G Hughes, Xochitl R Longstaff, Shanpeng Li, Yaroslav A Gofnung, Pouyan Famini, James X Wu, Michael W Yeh, Masha J Livhits
Zitieren
APA
Kim, N. E., Raghunathan, R. S., Hughes, E. G., Longstaff, X. R., Tseng, C. H., Li, S., Cheung, D. S., Gofnung, Y. A., Famini, P., Wu, J. X., Yeh, M. W., & Livhits, M. J. (2023). Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3. The Journal of Clinical Endocrinology & Metabolism, 108(9), e698-e703. https://doi.org/10.1210/clinem/dgad181
Vancouver
Kim NE, Raghunathan RS, Hughes EG, Longstaff XR, Tseng CH, Li S, et al. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3. The Journal of Clinical Endocrinology & Metabolism. 2023;108(9):e698-e703. doi:10.1210/clinem/dgad181
BibTeX
@article{Kim2023,
author = {Kim, Na Eun and Raghunathan, Rajam S and Hughes, Elena G and Longstaff, Xochitl R and Tseng, Chi-Hong and Li, Shanpeng and Cheung, Dianne S and Gofnung, Yaroslav A and Famini, Pouyan and Wu, James X and Yeh, Michael W and Livhits, Masha J},
title = {Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {9},
pages = {e698--e703},
doi = {10.1210/clinem/dgad181}
}
EUVIMED